DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
AD1093983
Title:
Development of Dietary Polyphenol Preparations for Treating Veterans with Gulf War Illness
Descriptive Note:
Technical Report,30 Sep 2014,29 Sep 2019
Corporate Author:
Icahn School of Medicine at Mount Sinai New York United States
Report Date:
2019-12-01
Pagination or Media Count:
9.0
Abstract:
There are no treatments for Gulf War Illness GWI and there is an urgent need to develop novel interventions either to resolve underlying GWI mechanisms, or to alleviate major GWI clinical complications, particularly chronic fatigue, cognitive difficulties, muscle pain, as well asmood disturbances and sleep problems. Recent evidence from our group and from others revealed that certain dietary flavonoids may promote cognitive function andor alleviate chronic fatigue. We hypothesized that dietary supplementation with a Flavonoid Rich PreparationFRP, consisting of Concord Grape Juice CGJ, may help alleviate clinical complications of GWI, particularly chronic fatigue andor cognitive dysfunction. We propose to test the feasibility of dietary supplementation with FRP in Veterans with GWI, and to gather evidence supporting the efficacy of FRP in alleviating GWI-associated cognitive deficits and chronic fatigue. Purpose To conduct a randomized, double-blind Phase IIIA study to explore long-term dose compliance, safety, tolerability of FRP and to assess the efficacy of FRP in improving cognition function and alleviating chronic fatigue in Veterans with GWI. Scope Evidence gathered by our proposed studies will provide the necessary proof of principle data and support future development of broader efficacy studies of a specific, readily available nutritional supplementation regimen, FRP, for treating Veterans with GWI. Progress In fiscal year 5, we completed data collection for all participants consented prior to the enrollment closure date of July 19th, 2018. The final endpoint was completed on January 17th, 2019 and data analysis began shortly afterward. We are currently creating a manuscript describing our results to submit for publication in the future. To summarize our final enrollment numbers, we sent letters to 777 potential participants. Of those 777, we screened 72 potential participants with 46 of them screening eligible.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE
